Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

Blood

Volumn 108, Issue 10, 2006, Pages 3289-3294

  Attal, Michel ^a   Harousseau, Jean Luc ^b   Leyvraz, Serge ^b   Doyen, Chantal ^b   Hulin, Cyrille ^b   Benboubker, Lofti ^b   Agha, Ibrahim Yakoub ^b   Bourhis, Jean Henri ^b   Garderet, Laurent ^b   Pegourie, Brigitte ^b   Dumontet, Charles ^b   Renaud, Marc ^b   Voillat, Laurent ^b   Berthou, Christian ^b   Marit, Gerald ^b   Monconduit, Mathieu ^b   Caillot, Denis ^b   Grobois, Bernard ^b   Avet Loiseau, Herve ^b   Moreau, Philippe ^b   Facon, Thierry ^b   more..

^a CHU PURPAN   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; PAMIDRONIC ACID; THALIDOMIDE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; BONE NECROSIS; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 33751164196     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-05-022962     Document Type: Article

References (31)

1. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
2. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
3. Richardson PG, Jagannath S, Schlossman RL, et al. A multicenter, randomized phase II study to evaluate the efficacy and safety of two CDC-5013 dose regimens when used alone or in combination with Dexamethasone for the treatment of relapsed and refractory multiple myeloma [abstract]. Blood. 2002;100:104a.
4. Palumbo A, Bringhen S, Musto P, et al. Oral melphalan, and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006;367:825-831.
5. Facon T, Mary JY, Hulin C, et al. Major superiority of melphalan - prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]. Blood. 2005;106:230a.
6. Mateos MV, Hernandez M, Mediavilla JD, et al. A phase I/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma (MM) patients [abstract]. Blood. 2005;106:232a.
7. Dimopoulos M, Spencer A, Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]. Blood. 2005;106:6a.
8. Palumbo A, Falco P, Musto P, et al. Oral Revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma [abstract]. Blood. 2005;106:231a.
9. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335:91-97.
10. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
11. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227-9233.
12. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106:3755-3759.
13. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104:3052-3057.
14. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-3136.
15. Alexanian R, Balzerzac S, Haut A, et al. Remission maintenance therapy for multiple myeloma. Arch Intern Med. 1975;135:147-152.
16. Belch A, Shelley W, Bergsagel D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer. 1988;57:94-99.
17. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. The Myeloma Trialists' Collaborative Group. Br J Haematol. 2001;113:1020-1034.
18. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000;11:1427-1436.
19. 2 TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup Trial S9321 [abstract]. Blood. 2003;102:42a.
20. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99:3163-3168.
21. Shustik C, Belch A, Robinson S, et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group Study: MY.7 [abstract]. J Clin Oncol. 2004;145:6510a.
22. Barlogie B, Zangari M, Spencer T, et al. Thalidomide in the management of multiple myeloma. Semin Hematol. 2001;38:250-259.
23. Durie BG, Stephan DE. Low dose thalidomide alone and in combination: long term follow-up [abstract]. Blood. 2001;98:163a.
24. Coleman RE, Purohit OP. Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev. 1993;19:79-103.
25. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-493.
26. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
27. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
28. Stewart AK, Chen CI, Howson-Jan K, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res. 2004;10:8170-8176.
29. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
30. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
31. Avet-Loiseau H, Attal M, Moreau P, et al. A comprehensive analysis of cytogenetic abnormalities in myeloma: results of the FISH analysis of 1000 patients enrolled in the IFM99 trials [abstract]. Blood. 2005;106:185a.